What is the difference between ADALIMUMAB-AACF and ADALIMUMAB-ADAZ?

ADALIMUMAB-AACF and ADALIMUMAB-ADAZ are both TNF Inhibitors, so they work through the same broad mechanism. They differ in dosing, half-life, side-effect frequency, and how individual patients tolerate them. See the head-to-head sections below for the specifics.

Is IDACIO the same as HYRIMOZ?

No. IDACIO (ADALIMUMAB-AACF) and HYRIMOZ (ADALIMUMAB-ADAZ) are distinct medications. They are sometimes confused because of similar branding or because they treat overlapping conditions, but they have different active ingredients and different safety profiles.

Which has fewer side effects, ADALIMUMAB-AACF or ADALIMUMAB-ADAZ?

Side-effect frequency varies by individual. The side-effect comparison section on this page shows FAERS-reported events for each drug side by side. FAERS is voluntary reporting, so it reflects what patients and clinicians chose to report, not absolute population risk.

Can I switch from ADALIMUMAB-AACF to ADALIMUMAB-ADAZ?

Switching medications should always be done under prescriber supervision. The "patient stories" section on this page includes accounts from people who have made the switch and what their transition felt like, but those are individual experiences, not protocols.

ADALIMUMAB-AACF vs ADALIMUMAB-ADAZ

Compare ADALIMUMAB-AACF (IDACIO) and ADALIMUMAB-ADAZ (HYRIMOZ) — clinical data, side effects, and patient experiences.

ADALIMUMAB-AACF

IDACIO · TNF Inhibitor

How it works

12.1 Mechanism of Action Adalimumab products bind specifically to TNF-alpha and block its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab products also lyse...

Approved for

1 INDICATIONS AND USAGE IDACIO is a tumor necrosis factor (TNF) blocker indicated for: • Rheumatoid Arthritis (RA) ( 1.1 ): reducing signs and symptoms

inducing major clinical response

inhibiting the progression of structural damage

OralTablet

ADALIMUMAB-ADAZ

HYRIMOZ · TNF Inhibitor

How it works

12.1 Mechanism of Action Adalimumab products bind specifically to TNF-alpha and block its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab products also lyse...

Approved for

1 INDICATIONS AND USAGE HYRIMOZ is a tumor necrosis factor (TNF)-blocker indicated for: • Reducing signs and symptoms

inducing major clinical response

inhibiting the progression of structural damage

SubcutaneousTablet

Quick Comparison

ADALIMUMAB-AACFADALIMUMAB-ADAZ

Drug Class

TNF Inhibitor

Route

Oral

Subcutaneous

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

ADALIMUMAB-AACF

Drug Not Working

1-10%

Diarrhea

1-10%

Abdominal Pain

1-10%

Injection Site Pain

1-10%

Joint Pain

1-10%

Upper Respiratory Infection

1-10%

Fatigue

0.1-1%

ADALIMUMAB-ADAZ

Drug Not Working

>10%

Fatigue

1-10%

Joint Pain

1-10%

Rash

1-10%

Condition Worsened

1-10%

Diarrhea

1-10%

Nausea

1-10%

Headache

1-10%

FDA Warnings

ADALIMUMAB-AACF

5 WARNINGS AND PRECAUTIONS • Serious infections: Do not start IDACIO during an active infection
If an infection develops, monitor carefully, and stop IDACIO if infection becomes serious
2 ) • Anaphylaxis or serious hypersensitivity reactions may occur ( 5
1 Serious Infections Patients treated with adalimumab products including IDACIO are at increased risk for developing serious infections involving various organ systems and sites that may lead to hospitalization or death

ADALIMUMAB-ADAZ

5 WARNINGS AND PRECAUTIONS • Serious infections: Do not start HYRIMOZ during an active infection
If an infection develops, monitor carefully, and stop HYRIMOZ if infection becomes serious
2) • Anaphylaxis or serious hypersensitivity reactions may occur
1 Serious Infections Patients treated with adalimumab products, including HYRIMOZ, are at increased risk for developing serious infections involving various organ systems and sites that may lead to hospitalization or death

Clinical Trial Data

No head-to-head clinical studies found for ADALIMUMAB-AACF vs ADALIMUMAB-ADAZ.

ADALIMUMAB-AACF vs ADALIMUMAB-ADAZ: What You Should Know

Key Differences

Both ADALIMUMAB-AACF and ADALIMUMAB-ADAZ belong to the TNF Inhibitor class. While they share a similar mechanism of action, differences in pharmacokinetics, dosing, and side effect profiles may make one more suitable than the other for individual patients. ADALIMUMAB-AACF is administered via Oral, whereas ADALIMUMAB-ADAZ uses Subcutaneous. Route of administration can affect onset of action and patient adherence.

Shared Indications

Both medications are approved for inducing major clinical response, inhibiting the progression of structural damage, inhibiting the progression of structural damage, posterior. When two drugs treat the same condition, the choice between them often depends on the patient's medical history, other medications, tolerability, and prescriber preference.

Safety Considerations

ADALIMUMAB-AACF carries 4 FDA warnings. ADALIMUMAB-ADAZ carries 4 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.

Related Comparisons

ADALIMUMAB-ADAZ vs ADALIMUMAB-ADBM→ADALIMUMAB-AACF vs ADALIMUMAB-ADBM→ADALIMUMAB-ADAZ vs ADALIMUMAB-RYVK→ADALIMUMAB-AACF vs ADALIMUMAB-RYVK→ADALIMUMAB-ADAZ vs ADALIMUMAB-BWWD→ADALIMUMAB-ADAZ vs ADALIMUMAB-FKJP→

Primary sources

Every figure on this comparison links back to its primary source. See data sources and methodology for the full provenance trail.

ADALIMUMAB-AACF: DailyMed label · FAERS adverse events · ClinicalTrials.gov
ADALIMUMAB-ADAZ: DailyMed label · FAERS adverse events · ClinicalTrials.gov

Loading comparison data...

ADALIMUMAB-AACF vs ADALIMUMAB-ADAZ

Compare ADALIMUMAB-AACF (IDACIO) and ADALIMUMAB-ADAZ (HYRIMOZ) — clinical data, side effects, and patient experiences.

ADALIMUMAB-AACF

IDACIO · TNF Inhibitor

How it works

12.1 Mechanism of Action Adalimumab products bind specifically to TNF-alpha and block its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab products also lyse...

Approved for

1 INDICATIONS AND USAGE IDACIO is a tumor necrosis factor (TNF) blocker indicated for: • Rheumatoid Arthritis (RA) ( 1.1 ): reducing signs and symptoms

inducing major clinical response

inhibiting the progression of structural damage

OralTablet

ADALIMUMAB-ADAZ

HYRIMOZ · TNF Inhibitor

How it works

12.1 Mechanism of Action Adalimumab products bind specifically to TNF-alpha and block its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab products also lyse...

Approved for

1 INDICATIONS AND USAGE HYRIMOZ is a tumor necrosis factor (TNF)-blocker indicated for: • Reducing signs and symptoms

inducing major clinical response

inhibiting the progression of structural damage

SubcutaneousTablet

Quick Comparison

ADALIMUMAB-AACFADALIMUMAB-ADAZ

Drug Class

TNF Inhibitor

Route

Oral

Subcutaneous

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

ADALIMUMAB-AACF

Drug Not Working

1-10%

Diarrhea

1-10%

Abdominal Pain

1-10%

Injection Site Pain

1-10%

Joint Pain

1-10%

Upper Respiratory Infection

1-10%

Fatigue

0.1-1%

ADALIMUMAB-ADAZ

Drug Not Working

>10%

Fatigue

1-10%

Joint Pain

1-10%

Rash

1-10%

Condition Worsened

1-10%

Diarrhea

1-10%

Nausea

1-10%

Headache

1-10%

FDA Warnings

ADALIMUMAB-AACF

5 WARNINGS AND PRECAUTIONS • Serious infections: Do not start IDACIO during an active infection
If an infection develops, monitor carefully, and stop IDACIO if infection becomes serious
2 ) • Anaphylaxis or serious hypersensitivity reactions may occur ( 5
1 Serious Infections Patients treated with adalimumab products including IDACIO are at increased risk for developing serious infections involving various organ systems and sites that may lead to hospitalization or death

ADALIMUMAB-ADAZ

5 WARNINGS AND PRECAUTIONS • Serious infections: Do not start HYRIMOZ during an active infection
If an infection develops, monitor carefully, and stop HYRIMOZ if infection becomes serious
2) • Anaphylaxis or serious hypersensitivity reactions may occur
1 Serious Infections Patients treated with adalimumab products, including HYRIMOZ, are at increased risk for developing serious infections involving various organ systems and sites that may lead to hospitalization or death

Clinical Trial Data

No head-to-head clinical studies found for ADALIMUMAB-AACF vs ADALIMUMAB-ADAZ.

ADALIMUMAB-AACF vs ADALIMUMAB-ADAZ: What You Should Know

Key Differences

Shared Indications

Safety Considerations

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.